Comparative Pharmacology
Head-to-head clinical analysis: METATENSIN 2 versus SERPASIL APRESOLINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METATENSIN 2 versus SERPASIL APRESOLINE.
METATENSIN #2 vs SERPASIL-APRESOLINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
METATENSIN #2 contains reserpine and methyclothiazide. Reserpine inhibits vesicular monoamine transporter (VMAT), depleting catecholamines from peripheral neurons. Methyclothiazide inhibits sodium-chloride symporter in distal convoluted tubule, reducing fluid volume.
Combination of reserpine (depletes catecholamines from sympathetic nerve endings) and hydralazine (direct vasodilator, increases cGMP via NO).
1-2 tablets orally every 12 hours; each tablet contains reserpine 0.1 mg, hydralazine 25 mg, hydrochlorothiazide 15 mg.
1 tablet (containing reserpine 0.1 mg and hydralazine 25 mg) orally once daily; may increase to twice daily if needed. Maximum dose: 2 tablets per day.
None Documented
None Documented
12 hours (terminal); clinical context: twice-daily dosing maintains stable plasma levels
Reserpine: ~50-100 hours (biphasic; terminal phase 4.5-11 days due to enterohepatic circulation and tissue binding). Hydralazine: 2-8 hours (rapid acetylators 30-50 min, slow acetylators 2-8 hours); longer in renal impairment.
Renal (80% unchanged, 15% as glucuronide metabolite); biliary/fecal (5%)
Reserpine: <1% unchanged in urine; extensive hepatic metabolism followed by renal and fecal excretion. Hydralazine: 80-90% renal; 10% fecal; 1-2% unchanged in urine; polymorphic acetylation (rapid/slow acetylators) affects clearance.
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination